UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2019
EVOKE PHARMA, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
|
001-36075 |
|
20-8447886 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|||
|
420 Stevens Avenue, Suite 370 Solana Beach, California |
|
92075 |
||
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code: (858) 345-1494
(Former Name or Former Address, if Changed Since Last Report.)
|
Securities registered pursuant to Section 12(b) of the Exchange Act |
||
|
Title of each class |
Trading symbol |
Name of each exchange on which registered |
|
Common Stock, par value $0.0001 per share |
EVOK |
The Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 7, 2019, Evoke Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2019. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
|
Description |
|
99.1 |
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
EVOKE PHARMA, INC. |
||
|
|
|
|
|
|||
|
Date: November 7, 2019 |
|
|
|
By: |
|
/s/ Matthew J. D’Onofrio |
|
|
|
|
|
Name: |
|
Matthew J. D’Onofrio |
|
|
|
|
|
Title: |
|
Executive Vice President, |
Exhibit 99.1
|
|
|
Investor Contact: The Ruth Group Tram Bui Tel: 646-536-7035 tbui@theruthgroup.com
|
|
|
||
|
|
Evoke Pharma Reports Third Quarter 2019 Financial Results
Gimoti NDA resubmission on track for fourth quarter 2019
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2019.
“We made significant progress toward addressing the regulatory requests from the U.S. Food and Drug Administration (FDA) during the third quarter, and we continue to prepare for the resubmission of our New Drug Application (NDA) for Gimoti during the fourth quarter,” said David A. Gonyer, R.Ph., President and CEO of Evoke Pharma, Inc. “We successfully completed manufacturing of commercial scale batches of Gimoti, which allows us to collect Chemistry, Manufacturing and Controls data as well as undertaking the analysis of pump performance characteristics on the nasal spray devices that will be used to support the NDA and bring us one step closer to commercial readiness. In addition, we believe that we have sufficient capital to support our operations into the second quarter of 2020.”
Third Quarter 2019 Financial Review
For the third quarter of 2019, net loss was approximately $1.6 million, or $0.07 per share, compared to a net loss of approximately $1.5 million, or $0.09 per share for the third quarter of 2018.
Research and development expenses totaled approximately $0.8 million for the third quarter of 2019, compared to approximately $0.6 million for the third quarter of 2018. Research and development expenses were primarily related to responding to requests for additional information from FDA for the Gimoti NDA and manufacturing registration batches of Gimoti.
For the third quarter of 2019, general and administrative expenses were approximately $0.8 million compared to approximately $0.9 million for the third quarter of 2018.
Total operating expenses for the third quarter of 2019 were approximately $1.6 million, compared to total operating expenses of approximately $1.5 million for the third quarter of 2018.
As of September 30, 2019, the Company’s cash and cash equivalents were approximately $6.5 million.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat Gastrointestinal (GI) disorders and diseases. The Company is developing Gimoti, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Metoclopramide is currently available only in oral and injectable formulations and is the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokePharma.com for more information.
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: the potential for an NDA resubmission and the timing thereof and Evoke’s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke’s resubmission of the NDA may be delayed and Evoke cannot be certain that FDA will accept or approve an NDA resubmission for Gimoti; Evoke may be unable to timely and successfully address the deficiencies raised in the CRL, including as a result of adverse findings from a root cause analysis or data from newly manufactured product batches; FDA may not agree with Evoke's conclusion of the root cause analysis or may require Evoke to conduct additional studies; the inherent risks of clinical development of Gimoti; Evoke’s dependence on third parties for the manufacture of Gimoti and analysis of the PK data; Evoke is entirely dependent on the success of Gimoti; Evoke will require substantial additional funding to continue its operations beyond the second quarter of 2020, and may be unable to raise capital or obtain funds when needed, including to fund ongoing operations; Evoke could face significant additional costs due to litigation or other events; Evoke’s ability to maintain the continued listing of its common stock on the Nasdaq Capital Market; and other risks detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
(Financial Statements to Follow)
|
|
|
September 30, 2019 |
|
|
December 31, 2018 |
|
||
|
|
|
(Unaudited) |
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
6,504,802 |
|
|
$ |
5,319,004 |
|
|
Prepaid expenses |
|
|
775,607 |
|
|
|
329,218 |
|
|
Other current assets |
|
|
11,551 |
|
|
— |
|
|
|
Total current assets |
|
|
7,291,960 |
|
|
|
5,648,222 |
|
|
Operating lease right-of-use asset |
|
|
35,398 |
|
|
— |
|
|
|
Other assets |
|
— |
|
|
|
11,551 |
|
|
|
Total assets |
|
$ |
7,327,358 |
|
|
$ |
5,659,773 |
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders' equity |
|
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
|
$ |
1,154,520 |
|
|
$ |
476,202 |
|
|
Accrued compensation |
|
|
964,243 |
|
|
|
1,158,251 |
|
|
Operating lease liability |
|
|
35,398 |
|
|
— |
|
|
|
Total current liabilities |
|
|
2,154,161 |
|
|
|
1,634,453 |
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
|
Common stock |
|
|
2,423 |
|
|
|
1,743 |
|
|
Additional paid-in capital |
|
|
89,482,936 |
|
|
|
82,628,312 |
|
|
Accumulated deficit |
|
|
(84,312,162 |
) |
|
|
(78,604,735 |
) |
|
Total stockholders' equity |
|
|
5,173,197 |
|
|
|
4,025,320 |
|
|
Total liabilities and stockholders' equity |
|
$ |
7,327,358 |
|
|
$ |
5,659,773 |
|
|
|
|
|
|
|
|
|
|
|
Condensed Statements of Operations
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
822,444 |
|
|
$ |
625,497 |
|
|
$ |
2,774,924 |
|
|
$ |
3,399,654 |
|
|
General and administrative |
|
|
814,218 |
|
|
|
897,060 |
|
|
|
2,955,371 |
|
|
|
2,846,611 |
|
|
Total operating expenses |
|
|
1,636,662 |
|
|
|
1,522,557 |
|
|
|
5,730,295 |
|
|
|
6,246,265 |
|
|
Loss from operations |
|
|
(1,636,662 |
) |
|
|
(1,522,557 |
) |
|
|
(5,730,295 |
) |
|
|
(6,246,265 |
) |
|
Other income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
8,597 |
|
|
|
3,089 |
|
|
|
22,868 |
|
|
|
7,425 |
|
|
Gain from change in fair value of warrant liability |
|
— |
|
|
— |
|
|
— |
|
|
|
433,392 |
|
|||
|
Total other income |
|
|
8,597 |
|
|
|
3,089 |
|
|
|
22,868 |
|
|
|
440,817 |
|
|
Net loss |
|
$ |
(1,628,065 |
) |
|
$ |
(1,519,468 |
) |
|
$ |
(5,707,427 |
) |
|
|
(5,805,448 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share of common stock, basic and diluted |
|
$ |
(0.07 |
) |
|
$ |
(0.09 |
) |
|
$ |
(0.26 |
) |
|
$ |
(0.36 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares used to compute basic and diluted net loss per share |
|
|
24,128,060 |
|
|
|
17,129,649 |
|
|
|
21,623,648 |
|
|
|
16,327,385 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|